Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation
© 2024 Cosson et al..
NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor functional characterization of most NLRP3 variants hinders diagnosis despite efficient anti-IL-1 treatments. Additionally, while NLRP3 is controlled by priming and activation signals, gain-of-functions have only been investigated in response to priming. Here, we characterize 34 NLRP3 variants in vitro, evaluating their activity upon induction, priming, and/or activation signals, and their sensitivity to four inhibitors. We highlight the functional diversity of the gain-of-function mutants and describe four groups based on the signals governing their activation, correlating partly with the symptom severity. We identify a new group of NLRP3 mutants responding to the activation signal without priming, associated with frequent misdiagnoses. Our results identify key NLRP3 residues controlling inflammasome activity and sensitivity to inhibitors, and antagonistic mechanisms with broader efficacy for therapeutic strategies. They provide new insights into NLRP3 activation, an explanatory mechanism for NLRP3-AID heterogeneity, and original tools for NLRP3-AID diagnosis and drug development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:221 |
|---|---|
| Enthalten in: |
The Journal of experimental medicine - 221(2024), 5 vom: 06. März |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Inflammasomes |
|---|
| Anmerkungen: |
Date Completed 27.03.2024 Date Revised 29.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1084/jem.20231200 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370198034 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370198034 | ||
| 003 | DE-627 | ||
| 005 | 20240330001433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1084/jem.20231200 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM370198034 | ||
| 035 | |a (NLM)38530241 | ||
| 035 | |a (PII)e20231200 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cosson, Camille |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Cosson et al. | ||
| 520 | |a NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor functional characterization of most NLRP3 variants hinders diagnosis despite efficient anti-IL-1 treatments. Additionally, while NLRP3 is controlled by priming and activation signals, gain-of-functions have only been investigated in response to priming. Here, we characterize 34 NLRP3 variants in vitro, evaluating their activity upon induction, priming, and/or activation signals, and their sensitivity to four inhibitors. We highlight the functional diversity of the gain-of-function mutants and describe four groups based on the signals governing their activation, correlating partly with the symptom severity. We identify a new group of NLRP3 mutants responding to the activation signal without priming, associated with frequent misdiagnoses. Our results identify key NLRP3 residues controlling inflammasome activity and sensitivity to inhibitors, and antagonistic mechanisms with broader efficacy for therapeutic strategies. They provide new insights into NLRP3 activation, an explanatory mechanism for NLRP3-AID heterogeneity, and original tools for NLRP3-AID diagnosis and drug development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a NLR Family, Pyrin Domain-Containing 3 Protein |2 NLM | |
| 650 | 7 | |a Inflammasomes |2 NLM | |
| 700 | 1 | |a Riou, Romane |e verfasserin |4 aut | |
| 700 | 1 | |a Patoli, Danish |e verfasserin |4 aut | |
| 700 | 1 | |a Niu, Tingting |e verfasserin |4 aut | |
| 700 | 1 | |a Rey, Amaury |e verfasserin |4 aut | |
| 700 | 1 | |a Groslambert, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a De Rosny, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Chatre, Elodie |e verfasserin |4 aut | |
| 700 | 1 | |a Allatif, Omran |e verfasserin |4 aut | |
| 700 | 1 | |a Henry, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Venet, Fabienne |e verfasserin |4 aut | |
| 700 | 1 | |a Milhavet, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Boursier, Guilaine |e verfasserin |4 aut | |
| 700 | 1 | |a Belot, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Jamilloux, Yvan |e verfasserin |4 aut | |
| 700 | 1 | |a Merlin, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Duquesne, Agnès |e verfasserin |4 aut | |
| 700 | 1 | |a Grateau, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Savey, Léa |e verfasserin |4 aut | |
| 700 | 1 | |a Jacques Maria, Alexandre Thibault |e verfasserin |4 aut | |
| 700 | 1 | |a Pagnier, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Poutrel, Solène |e verfasserin |4 aut | |
| 700 | 1 | |a Lambotte, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Mallebranche, Coralie |e verfasserin |4 aut | |
| 700 | 1 | |a Ardois, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Richer, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Lemelle, Irène |e verfasserin |4 aut | |
| 700 | 1 | |a Rieux-Laucat, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Bader-Meunier, Brigitte |e verfasserin |4 aut | |
| 700 | 1 | |a Amoura, Zahir |e verfasserin |4 aut | |
| 700 | 1 | |a Melki, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Cuisset, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Touitou, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Geyer, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Georgin-Lavialle, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Py, Bénédicte F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of experimental medicine |d 1896 |g 221(2024), 5 vom: 06. März |w (DE-627)NLM000005967 |x 1540-9538 |7 nnns |
| 773 | 1 | 8 | |g volume:221 |g year:2024 |g number:5 |g day:06 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1084/jem.20231200 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 221 |j 2024 |e 5 |b 06 |c 03 | ||